"Receptors, KIR" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of receptors found on NK CELLS that have specificity for a variety of HLA ANTIGENS. KIR receptors contain up to three different extracellular immunoglobulin-like domains referred to as D0, D1, and D2 and play an important role in blocking NK cell activation against cells expressing the appropriate HLA antigens thus preventing cell lysis. Although they are often referred to as being inhibitory receptors, a subset of KIR receptors may also play an activating role in NK cells.
Descriptor ID |
D054340
|
MeSH Number(s) |
D12.776.543.750.705.895.500
|
Concept/Terms |
Receptors, KIR- Receptors, KIR
- Killer Inhibitory Receptors
- Inhibitory Receptors, Killer
- Receptors, Killer Inhibitory
- Receptor, p58 NK Cell
- p58 Natural Killer Cell Receptor
- KIR Receptor
- Receptor, KIR
- p58 NK Cell Inhibitory Receptor
- Receptor, Killer Inhibitory
- Killer Inhibitory Receptor
- Inhibitory Receptor, Killer
- Killer Immunoglobulin-Like Receptor
- Immunoglobulin-Like Receptor, Killer
- Killer Immunoglobulin Like Receptor
- Receptor, Killer Immunoglobulin-Like
- Killer Cell Immunoglobulin-Like Receptor
- Killer Cell Immunoglobulin Like Receptor
- KIR Family Receptors
- Family Receptors, KIR
- Receptors, KIR Family
- KIR Receptors
- Killer Immunoglobulin-Like Receptor (KIR) Family of Receptors
- Killer Cell Immunoglobulin-Like Receptors
- Killer Cell Immunoglobulin Like Receptors
- p58 NK Cell Receptor
- p58 NK Cell Receptors
|
Below are MeSH descriptors whose meaning is more general than "Receptors, KIR".
Below are MeSH descriptors whose meaning is more specific than "Receptors, KIR".
This graph shows the total number of publications written about "Receptors, KIR" by people in this website by year, and whether "Receptors, KIR" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1999 | 0 | 1 | 1 |
2002 | 0 | 1 | 1 |
2009 | 0 | 1 | 1 |
2010 | 1 | 0 | 1 |
2011 | 1 | 0 | 1 |
2012 | 1 | 1 | 2 |
2013 | 1 | 0 | 1 |
2014 | 1 | 0 | 1 |
2015 | 1 | 0 | 1 |
2016 | 3 | 0 | 3 |
2017 | 1 | 1 | 2 |
2018 | 1 | 3 | 4 |
2019 | 1 | 0 | 1 |
2020 | 0 | 1 | 1 |
2022 | 0 | 1 | 1 |
2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, KIR" by people in Profiles.
-
Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial. Cancer Immunol Immunother. 2023 Jul; 72(7):2099-2111.
-
Donor selection for KIR alloreactivity is associated with superior survival in haploidentical transplant with PTCy. Front Immunol. 2022; 13:1033871.
-
Diversity of peripheral blood human NK cells identified by single-cell RNA sequencing. Blood Adv. 2020 04 14; 4(7):1388-1406.
-
Killer Cell Immunoglobulin-Like Receptors (KIRs) Genotype and Haplotype Analysis in Iranians with Non-Melanoma Skin Cancers Iran Biomed J. 2019 09; 23(5):330-7.
-
The Optimal Killer Cell Immunoglobulin-Like Receptor Donor-We Can Recognize, but Can We Search? Biol Blood Marrow Transplant. 2019 01; 25(1):e3-e4.
-
Optimal Donor Selection During Verification Process: Which Factors Are Worth Knowing? Transplant Proc. 2018 Dec; 50(10):3082-3087.
-
A Pilot Trial of Lirilumab With or Without Azacitidine for Patients With Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2018 10; 18(10):658-663.e2.
-
NK cell therapy for hematologic malignancies. Int J Hematol. 2018 Mar; 107(3):262-270.
-
Allogeneic Hematopoietic Cell Transplantation for Myeloma: When and in Whom Does It Work. Curr Hematol Malig Rep. 2017 04; 12(2):126-135.
-
Improved full-length killer cell immunoglobulin-like receptor transcript discovery in Mauritian cynomolgus macaques. Immunogenetics. 2017 05; 69(5):325-339.